Português | English

ISSN (Print): 2359-4802 | ISSN (Online): 2359-5647

Article's Author

1 result(s) for: Carlos Vicente Serrano Jr

Reduction of in long-term mortality related to higher doses of atorvastatin in patients with acute coronary syndromes

Redução de mortalidade em longo prazo relacionada a doses mais elevadas de atorvastatina em pacientes com síndrome coronariana aguda

Alexandre de Matos Soeiro; Aline Siqueira Bossa; Maria Cristina César; Cindel Nogueira Zullino; Tatiana de Carvalho Andreucci Torres Leal; Bruno Biselli; Maria Carolina Feres de Almeida Soeiro; Carlos Vicente Serrano Jr.; Múcio Tavares Oliveira Jr.

Int J Cardiovasc Sci.2016;29(4):280-287 : Original Article


BACKGROUND: Recent experimental studies have described reduction in inflammatory markers related to higher doses of statins in patients with acute coronary syndromes (ACS). However, the clinical implication of the dose of statin in the acute phase of the ACS remains uncertain.
OBJECTIVE: To compare the outcomes in short and long terms among patients with acute coronary syndromes that received higher doses of atorvastatin versus low doses of atorvastatin started in the first 24 hours of hospital admission.
METHODS: For such, the patients were divided in two groups: group I (N = 464): atorvastatin dose: 40 mg/day. Demographic data, laboratory exams, medications used and coronary treatment adopted were obtained. Statistical analysis: The primary outcome was mortality from all causes. The comparison between groups was made by T-test and Q-square. Multivariative analysis of in-hospital outcomes were determined by logistic regression, considered significant when p < 0.05. In long-term, the mortality and combined events by the Kaplan-Meier method were assessed, with median follow-up of 8.79 months.
RESULTS: In the analysis of in-hospital outcomes, no significant differences were observed between groups I and II. In the long-term, group II presented lower mortality in comparison with group 9 (8.4% vs. 3.9%, p = 0.013).
CONCLUSIONS: Favorable and significant differences were observed in relation to long-term mortality in patients with ACS that received high doses of atorvastatin since the acute phase. (Int J Cardiovasc Sci. 2016;29(4):280-287)